Stocks›Healthcare›NNNN

NNNN

Anbio Biotechnology
NasdaqResearch view

Anbio Biotechnology operates in the In Vitro & In Vivo Diagnostic Substances industry.

$4.90+1.45%
Oct 6 close · 1D EOD · Databento
HealthcareIn Vitro & In Vivo Diagnostic SubstancesMicro-capSEC EDGAR FY 2025-12-31

The numbers · FY2025, filed

SEC EDGAR
Market cap$242M
Revenue$8.6M+5.60%
Net income$6.4M
EPS, diluted$0.15+162.50%
Gross margin87.2%
Operating margin66.7%
All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31
SectorHealthcare
Market Cap$242.4M
Enterprise Value$234.6M
Income$6.4M
Sales$8.6M
Book/sh—
Cash/sh—
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio—
Current Ratio344.31
Debt/Eq—
EPS (ttm)$0.15
EPS this Y162.5%
EPS past 3/5Y-98.9%
Sales past 3/5Y-28.4%
EPS Y/Y TTM162.5%
Sales Y/Y TTM5.6%
Shs Outstand—
ROA21.2%
ROE21.2%
ROIC20.4%
Gross Margin87.2%
Oper. Margin66.7%
Profit Margin74.1%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$23.5M
FY22
$6.7M
FY23
$8.2M
FY24
$8.6M
FY25

Operating leverage — margins

GrossOperatingNet
0%50%100%87%67%74%FY22FY23FY24FY25
Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 4 FY · tap a row to explain it
USDFY2022FY2023FY2024FY2025

Same industry

In the screener →

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.